Abstract
In this study, the in vitro antitumor activity of chenodeoxycholic acid-verticinone ester (CDCA-Ver), a novel compound and its underlying mechanisms were evaluated. Results showed that CDCA-Ver significantly inhibited HepG2 cell viability in a both dose- and time-dependent manner, moreover CDCA-Ver induced apoptotic cell death and G0/G1 cell cycle arrest in HepG2 cells. ROS generation, loss of balance of Bax/Bcl-2 ratio, loss of mitochondrial transmembrane potential, activation of caspases and elevation of intracellular free Ca2+ concentration were involved in the CDCA-Ver induced apoptosis pathway in HepG2 cells. We concluded that CDCA-Ver may be a potential candidate for the therapy of cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
